Skip to main content

Table 4 MHT use at study entry and 10-year survival by intrinsic-like subtypes

From: Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study

 

Breast cancer deaths overall

(n = 634)

Luminal A-like

(n = 148)

Luminal B-like

(n = 104)

HER2 + 

(n = 32)

TNBC

(n = 81)

phet3

 

n

HR (95% CI)1,2

n

HR (95% CI)1,2

n

HR (95% CI)1,2

n

HR (95% CI)1,2

n

HR (95% CI)1,2

 

MHT use overall

           

Never use

356

Ref

76

Ref

62

Ref

19

Ref

54

Ref

 

  Ever use

278

0.95 (0.81–1.11)

72

1.20 (0.86–1.67)

42

0.78 (0.52–1.17)

13

0.90 (0.44–1.86)

27

0.56 (0.35–0.90)

0.10

    Current

226

0.97 (0.82–1.15)

58

1.28 (0.90–1.82)

32

0.77 (0.50–1.19)

13

1.14 (0.55–2.35)

16

0.41 (0.24–0.73)

0.02

    Former

52

0.85 (0.63–1.13)

14

0.95 (0.53–1.68)

10

0.82 (0.42–1.62)

0

-

11

1.13 (0.59–2.20)

0.78

  Duration

           

     < 5 yrs

181

0.95 (0.79–1.14)

38

1.04 (0.70–1.54)

26

0.78 (0.49–1.25)

10

1.05 (0.48–2.29)

16

0.52 (0.30–0.92)

 

     ≥ 5 yrs

93

0.94 (0.74–1.18)

32

1.43 (0.93–2.19)

15

0.74 (0.42–1.32)

3

0.65 (0.19–2.24)

11

0.66 (0.34–1.28)

 

    Per 1 yr

630

0.99 (0.97–1.02)

146

1.03 (0.99–1.07)

103

0.98 (0.92–1.04)

32

0.93 (0.81–1.07)

81

0.95 (0.88–1.03)

0.12

ETP use

           

Never use

356

Ref

76

Ref

62

Ref

19

Ref

54

Ref

 

  Ever use

201

0.94 (0.79–1.12)

54

1.24 (0.86–1.77)

31

0.78 (0.50–1.22)

11

1.06 (0.49–2.26)

20

0.57 (0.34–0.96)

0.14

    Current

175

0.99 (0.82–1.19)

47

1.36 (0.94–1.99)

25

0.78 (0.49–1.26)

11

1.27 (0.59–2.72)

14

0.48 (0.26–0.87)

0.05

    Former

26

0.70 (0.47–1.05)

7

0.77 (0.35–1.67)

6

0.79 (0.34–1.85)

0

-

6

1.03 (0.44–2.44)

0.92

  Duration

           

     < 5 yrs

126

0.97 (0.79–1.19)

25

1.00 (0.63–1.58)

19

0.83 (0.49–1.40)

9

1.38 (0.61–3.09)

11

0.52 (0.27–1.01)

 

     ≥ 5 yrs

74

0.90 (0.70–1.16)

28

1.53 (0.98–2.39)

12

0.71 (0.38–1.33)

2

0.52 (0.12–2.27)

9

0.65 (0.32–1.34)

 

    Per 1 yr

556

0.99 (0.96–1.02)

129

1.04 (1.00–1.09)

93

0.98 (0.92–1.04)

30

0.93 (0.79–1.08)

74

0.95 (0.88–1.03)

0.08

  1. 1HRs of breast-cancer specific death
  2. 2Adjusted for age (underlying time scale), BMI, parity, age at first birth, age at menarche, family history, smoking, physical activity, education
  3. 3p heterogeneity between intrinsic-like subtypes; Wald test by competing risks analysis
  4. CI confidence interval, ETP estrogen-progestin therapy, HER2 human epidermal growth factor receptor 2, HR hazard ratio, MHT menopausal hormone therapy, TNBC triple-negative breast cancer
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us